To test this hypothesis, we assessed spatial distribution of 18F-fluoromisonidazole (FMISO) PET/CT uptake in the prostate prior to radiotherapy treatment in intermediate-risk prostate cancer patients and compared these results with anatomical imaging and Glut1 staining on biopsy specimens. The gene discussed is SLC2A1; the disease is prostate carcinoma.